SKIN
The Beauty Health Company [SKIN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SKIN Stock Summary
Top 10 Correlated ETFs
SKIN
Top 10 Correlated Stocks
SKIN
In the News
7 Short-Squeeze Stocks Set for a May Rally
A practice designed for only the most daring traders, the best short-squeeze stocks to buy now could yield tremendous gains. To be sure, approaching this sector means staring at the possibility of severe losses in the face.
The Beauty Health Company (SKIN) Q1 2023 Earnings Call Transcript
The Beauty Health Company (NASDAQ:SKIN ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Eduardo Rodriguez - Senior Director, M&A and Investor Relations Andrew Stanleick - President, Chief Executive Officer & Director Liyuan Woo - Chief Financial Officer Conference Call Participants Korinne Wolfmeyer - Piper Sandler & Co. Margaret Kaczor - William Blair & Company Olivia Tong - Raymond James & Associates Jonathan Block - Stifel, Nicolaus & Company Oliver Chen - TD Cowen Allen Gong - JPMorgan Chase & Co. Bruce Jackson - The Benchmark Company Linda Bolton-Weiser - D.A. Davidson & Co. Navann Ty - BNP Paribas Exane Kyle Rose - Canaccord Genuity Operator Good day, and welcome to the Beauty Health Company First Quarter 2023 Earnings Conference Call.
The Beauty Health Company: More Than Skin Deep
The company's core HydraFacial product is popular among consumers and beauticians. The company has a razor and blade business model with a lucrative and customisable consumables component.
7 Short-Squeeze Stocks That Could Make You Rich
While trading with the masses may generally be the wisest approach, contrarian gamblers may accrue dramatic profitability through short-squeeze stocks. To get everyone on the same page, coordinated investments in heavily shorted securities can potentially trigger ridiculous upside as bears panic out of their positions.
Why Is The Beauty Health Company Jumping Higher Today?
The medical device company is gaining traction with growing sales and profits.
7 Short-Squeeze Stocks to Buy Before They Soar
As much as we may recognize that short sellers perform a valuable service for the equities market, the concept of targeting short-squeeze stocks to buy just to penalize the pessimists carries cathartic value. Fundamentally, market bears operate like great white sharks.
The Beauty Health Company: A Good Long Term Bet
In 2023, revenue should benefit from healthy demand and an increasing footprint globally. Margins should benefit from operating leverage and normalized investment levels in 2023.
The Beauty Health Company (SKIN) Q3 2022 Earnings Call Transcript
The Beauty Health Company (NASDAQ:SKIN ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Eduardo Rodriguez - Senior Director of M&A and IR Andrew Stanleick - President and CEO Liyuan Woo - CFO Conference Call Participants Oliver Chen - Cowen Korinne Wolfmeyer - Piper Sandler Jon Block - Stifel Margaret Kaczor - William Blair Allen Gong - JPMorgan Ashley Helgans - Jefferies Kyle Rose - Canaccord Genuity Bruce Jackson - The Benchmark Company Devin Weinstein - Raymond James Linda Bolton Weiser - D.A. Davidson Operator Ladies and gentlemen, good morning, and welcome to Beauty Health Company Third Quarter 2022 Earnings Call.
The Beauty Health Company: A Compelling Mid To Long-Term Growth Story
The Beauty Health Company's new mid-term targets highlight the impressive (but achievable) growth opportunities at hand. As the model benefits from operating leverage, more revenue growth should yield significant margin expansion as well.
This High-Growth, Under-the-Radar Stock Has 80% Upside, According to Wall Street
BeautyHealth's HydraFacial platform is popular, management is building a solid track record, and the business is outperforming expectations.
SKIN Financial details
SKIN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.9 | 1.33 | 0.95 | 2.55 | 2.48 | |
| Net income per share | 0 | -0.01 | -0.23 | -3.67 | 0.3 | |
| Operating cash flow per share | -0.01 | 0.01 | -0.1 | -0.28 | -0.72 | |
| Free cash flow per share | -0.07 | -0.07 | -0.13 | -0.43 | -0.84 | |
| Cash per share | 0 | 0.06 | 0.08 | 8.83 | 3.85 | |
| Book value per share | 0 | -0.01 | -0.24 | 2.96 | 1.16 | |
| Tangible book value per share | 0 | -1.28 | -1.43 | 1.2 | 0 | |
| Share holders equity per share | 0 | -0.01 | -0.24 | 2.96 | 1.16 | |
| Interest debt per share | 0 | 1.65 | 1.9 | 7.3 | 5.19 | |
| Market cap | 1.36B | 1.36B | 1.42B | 2.47B | 1.34B | |
| Enterprise value | 0 | 1.54B | 1.63B | 2.3B | 1.53B | |
| P/E ratio | -4.29K | -829.87 | -48.61 | -6.58 | 30.25 | |
| Price to sales ratio | 12.1 | 8.16 | 11.91 | 9.49 | 3.67 | |
| POCF ratio | -1.52K | 786.64 | -114.05 | -86.99 | -12.6 | |
| PFCF ratio | -154.73 | -156.35 | -87.26 | -56.1 | -10.83 | |
| P/B Ratio | 0 | -1.13K | -47.34 | 8.16 | 7.83 | |
| PTB ratio | 0 | -1.13K | -47.34 | 8.16 | 7.83 | |
| EV to sales | 0 | 9.25 | 13.65 | 8.82 | 4.17 | |
| Enterprise value over EBITDA | 0 | 55.3 | -574.73 | -26.03 | -91.1 | |
| EV to operating cash flow | 0 | 892.24 | -130.69 | -80.93 | -14.32 | |
| EV to free cash flow | 0 | -177.34 | -100 | -52.19 | -12.31 | |
| Earnings yield | 0 | 0 | -0.02 | -0.15 | 0.03 | |
| Free cash flow yield | -0.01 | -0.01 | -0.01 | -0.02 | -0.09 | |
| Debt to equity | 0 | -188.38 | -8.44 | 3.03 | 4.88 | |
| Debt to assets | 0 | 1.01 | 1.13 | 0.75 | 0.83 | |
| Net debt to EBITDA | 0 | 6.55 | -73.21 | 1.95 | -10.96 | |
| Current ratio | 0 | 1.43 | 1.91 | 13.09 | 10.79 | |
| Interest coverage | 1 | 0.79 | -0.81 | -3.11 | -1.81 | |
| Income quality | 2.82 | -1.05 | 0.43 | 0.08 | -2.4 | |
| Dividend Yield | 0.07 | 0 | 0 | 0 | 0 | |
| Payout ratio | -311.39 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.16 | 0.16 | 0.26 | 0.38 | 0.29 | |
| Research and developement to revenue | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | |
| Intangibles to total assets | 0 | 0.7 | 0.67 | 0.15 | 0.17 | |
| Capex to operating cash flow | 8.81 | -6.03 | 0.31 | 0.55 | 0.16 | |
| Capex to revenue | -0.07 | -0.06 | -0.03 | -0.06 | -0.05 | |
| Capex to depreciation | -0.69 | -0.75 | -0.27 | -0.74 | -0.79 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.05 | 0.08 | |
| Graham number | 0 | 0.05 | 1.12 | 15.64 | 2.8 | |
| ROIC | 0 | 0.04 | -0.07 | 0.06 | 0.15 | |
| Return on tangible assets | 0 | -0.02 | -0.4 | -0.36 | 0.05 | |
| Graham Net | 0 | -1.54 | -1.71 | 0.41 | -1.03 | |
| Working capital | 0 | 16.35M | 28.17M | 924.46M | 715.98M | |
| Tangible asset value | 0 | -160.02M | -179.43M | 122.59M | 497K | |
| Net current asset value | 0 | -173.39M | -193.7M | 84.38M | -48.33M | |
| Invested capital | 0 | -157.1 | -7.23 | 2.43 | 4.38 | |
| Average receivables | 0 | 0 | 23.45M | 37.31M | 64.6M | |
| Average payables | 0 | 0 | 16.37M | 23.77M | 29.69M | |
| Average inventory | 0 | 0 | 21.32M | 29.23M | 75.85M | |
| Days sales outstanding | 0 | 51.96 | 71.06 | 72.17 | 77.59 | |
| Days payables outstanding | 0 | 86.57 | 130.02 | 135.48 | 95.83 | |
| Days of inventory on hand | 0 | 118.01 | 163.2 | 164.46 | 367.82 | |
| Receivables turnover | 0 | 7.02 | 5.14 | 5.06 | 4.7 | |
| Payables turnover | 0 | 4.22 | 2.81 | 2.69 | 3.81 | |
| Inventory turnover | 0 | 3.09 | 2.24 | 2.22 | 0.99 | |
| ROE | 0 | 1.36 | 0.97 | -1.24 | 0.26 | |
| Capex per share | -0.06 | -0.08 | -0.03 | -0.15 | -0.12 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.5 | 0.69 | 0.59 | 0.71 | 0.65 | |
| Net income per share | 0.22 | 0.05 | 0 | 0.03 | -0.17 | |
| Operating cash flow per share | -0.26 | -0.21 | -0.21 | -0.04 | -0.1 | |
| Free cash flow per share | -0.28 | -0.23 | -0.26 | -0.06 | -0.1 | |
| Cash per share | 5.71 | 5.45 | 4.54 | 4.11 | 4.02 | |
| Book value per share | 2.27 | 2.34 | 1.71 | 1.24 | 1.11 | |
| Tangible book value per share | 1.1 | 1.17 | 0.59 | 0 | -0.37 | |
| Share holders equity per share | 2.27 | 2.34 | 1.71 | 1.24 | 1.11 | |
| Interest debt per share | 4.98 | 5 | 4.99 | 5.46 | 5.71 | |
| Market cap | 2.54B | 1.94B | 1.78B | 1.26B | 1.67B | |
| Enterprise value | 2.43B | 1.87B | 1.84B | 1.44B | 1.89B | |
| P/E ratio | 19.55 | 61.1 | 3.39K | 82.41 | -18.83 | |
| Price to sales ratio | 33.71 | 18.72 | 20.02 | 12.82 | 19.38 | |
| POCF ratio | -66.08 | -61.86 | -56.62 | -233.19 | -128.55 | |
| PFCF ratio | -60.68 | -55.8 | -45.42 | -153.05 | -128.55 | |
| P/B Ratio | 7.44 | 5.5 | 6.89 | 7.33 | 11.33 | |
| PTB ratio | 7.44 | 5.5 | 6.89 | 7.33 | 11.33 | |
| EV to sales | 32.22 | 18.03 | 20.76 | 14.69 | 21.93 | |
| Enterprise value over EBITDA | -309.57 | 658.6 | -1.13K | 2.72K | -151.41 | |
| EV to operating cash flow | -63.16 | -59.59 | -58.69 | -267.24 | -145.47 | |
| EV to free cash flow | -58 | -53.75 | -47.09 | -175.39 | -145.47 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | -0.01 | |
| Free cash flow yield | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | |
| Debt to equity | 2.51 | 2.45 | 3.28 | 4.88 | 5.74 | |
| Debt to assets | 0.72 | 0.71 | 0.77 | 0.83 | 0.85 | |
| Net debt to EBITDA | 14.3 | -25.14 | -39.97 | 346.4 | -17.61 | |
| Current ratio | 14.25 | 11.44 | 11.68 | 10.79 | 10.35 | |
| Interest coverage | -3.81 | -0.55 | -1.23 | -1.52 | -5.09 | |
| Income quality | -1.18 | -3.95 | -239.7 | -1.41 | 0.58 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.35 | 0.27 | 0.27 | 0.29 | 0.35 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.02 | 0.01 | 0.03 | |
| Intangibles to total assets | 0.15 | 0.14 | 0.15 | 0.17 | 0.2 | |
| Capex to operating cash flow | 0.09 | 0.11 | 0.25 | 0.52 | 0 | |
| Capex to revenue | -0.05 | -0.03 | -0.09 | -0.03 | 0 | |
| Capex to depreciation | -0.57 | -0.74 | -1.36 | -0.5 | 0 | |
| Stock based compensation to revenue | 0.09 | 0.06 | 0.08 | 0.08 | 0.04 | |
| Graham number | 3.32 | 1.66 | 0.18 | 0.88 | 2.05 | |
| ROIC | 0.02 | 0 | 0 | 0.05 | 0.14 | |
| Return on tangible assets | 0.03 | 0.01 | 0 | 0 | -0.03 | |
| Graham Net | 0.48 | 0.37 | -0.32 | -1.1 | -1.51 | |
| Working capital | 913.46M | 908.7M | 815.99M | 715.98M | 676.2M | |
| Tangible asset value | 165.39M | 177.1M | 88.54M | 497K | -48.4M | |
| Net current asset value | 124.92M | 133.13M | 45.55M | -48.33M | -98.8M | |
| Invested capital | 2.19 | 2.13 | 2.91 | 4.38 | 5.1 | |
| Average receivables | 57M | 71.75M | 82.81M | 81.23M | 75.09M | |
| Average payables | 28.01M | 31.9M | 34.7M | 31.46M | 32.32M | |
| Average inventory | 41.15M | 60.28M | 87.62M | 109.07M | 119.27M | |
| Days sales outstanding | 74.67 | 70.35 | 85.84 | 71.33 | 75.5 | |
| Days payables outstanding | 103.36 | 103.97 | 107.72 | 82.83 | 95.87 | |
| Days of inventory on hand | 180.3 | 207.56 | 336.32 | 317.93 | 341.27 | |
| Receivables turnover | 1.21 | 1.28 | 1.05 | 1.26 | 1.19 | |
| Payables turnover | 0.87 | 0.87 | 0.84 | 1.09 | 0.94 | |
| Inventory turnover | 0.5 | 0.43 | 0.27 | 0.28 | 0.26 | |
| ROE | 0.1 | 0.02 | 0 | 0.02 | -0.15 | |
| Capex per share | -0.02 | -0.02 | -0.05 | -0.02 | 0 |
SKIN Frequently Asked Questions
What is The Beauty Health Company stock symbol ?
The Beauty Health Company is a US stock , located in Long beach of Ca and trading under the symbol SKIN
Is The Beauty Health Company buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26
What is SKIN stock prediction ?
What is The Beauty Health Company stock quote today ?
The Beauty Health Company stock price is $8.355 today.
Is The Beauty Health Company stock public?
Yes, The Beauty Health Company is a publicly traded company.
Company Profile
- Volume Average 1.76M
- Market Capitalization 1.11B
- Employee 1.03K
- CEO Mr. Andrew Stanleick
- Headquarters Long Beach,CA,US
- IPO Date 2020-11-20
-
Website
https://www.beautyhealth.com 
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
